Therefore, SHP2 inhibitor treatment may have better anti-tumorigenic effects than RTK inhibitor treatment, not only by blocking RTK signaling in tumor cells but also by enhancing anti-tumor immunity. The gene discussed is PTPN11; the disease is neoplasm.